Aanvaard alle cookies en geniet van de beste ervaring op onze website, zoals contentpersonalisatie en functies voor social media. Aanvaard enkel noodzakelijke cookies en ga voor minimaal gebruik van cookies terwijl je browst. Dit betekent wel dat sommige delen van de website mogelijk niet correct worden weergeven. Meer weten? Raadpleeg ons Privacybeleid.
15th EGA Regulatory and Scientific Affairs Conference had offered an update on recent regulatory developments, and answered the following answers:
- Looking to the future- EMA/HMA Strategy 2020 Work Plan- how will it impact the regulatory environment for pharmaceuticals?
- Tackling effects of the globalisation of pharmaceutical operations – challenges, opportunities and priorities
- Maintenance of medicinal products: is there a better way of handling it in practice?
- Borderline medicinal products - Do on-going changes to medical devices, food supplement legislations impact my products?
- How does the ICH 3QD guideline on elemental impurities affect my products?
- ISO IDMP is around the corner: are we set and ready to start with implementation?
Key Takeaways
- Regulatory implications of various changes in the legal and operational environment
- Electronic submission environment
Photos
Romuald Braun and Bernard Ferber at Amplexor's booth